查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372870

骨質疏鬆藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、給藥途徑、按應用、配銷通路、地區和競爭細分

Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Route of Administration, By Application, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球骨質疏鬆藥物市場價值為 160.9 億美元，預計在預測期內將出現顯著成長，預計到 2028 年年複合成長率 (CAGR) 為 5.73%。

骨質疏鬆症是一種以骨組織退化和骨強度下降為特徵的疾病。這種情況的診斷通常涉及使用各種影像技術，包括 X 光、電腦斷層掃描 (CT) 和磁振造影 (MRI)。

目前，有多種不同劑型的藥物可供選擇，從標準片劑到靜脈注射 (IV) 輸液，可緩解骨質疏鬆症的症狀。這些藥物有助於恢復骨吸收和形成之間的平衡，修復微小的骨缺損，降低骨折風險，並增強患者的整體肌肉力量。

市場概況
預測期 2024-2028
2022 年市場規模 160.9億美元
2028 年市場規模 223.6億美元
2023-2028 年年複合成長率 5.73%
成長最快的細分市場 網路藥房
最大的市場 北美洲

主要市場促進因素

骨質疏鬆症發生率增加

無可否認，骨質疏鬆症發生率的增加導致對骨質疏鬆症藥物的需求顯著增加。骨質疏鬆症的特徵是骨骼脆弱，更容易骨折，主要影響老年人，尤其是停經後婦女。由於荷爾蒙的變化會加速骨質流失，骨質疏鬆症對女性尤其是停經後女性的影響尤其嚴重。隨著女性人口的成長，骨質疏鬆症的盛行率也在增加，這直接刺激了對旨在控制和緩解病情的藥物的需求。

不斷增加的臨床試驗和不斷增加的老年人口

骨質疏鬆症在老年人中最常見，尤其是停經後婦女。隨著全球人口老化，面臨骨質疏鬆症風險的人數大幅增加。隨著年齡的成長，骨密度自然下降，使得骨質疏鬆症在老年人中更常見。 - 隨著主要參與者繼續投資增強其技術能力，研發領域存在著巨大且不斷成長的市場機會。這些投資旨在推動創新進步，滿足各行業不斷變化的需求。此外，市場也受到骨質疏鬆症盛行率上升的影響，骨質疏鬆症是一種以骨骼衰弱為特徵的疾病。這一趨勢催生了對能夠有效應對骨質疏鬆症挑戰的創新解決方案的需求。

提高意識和診斷

醫學知識和診斷技術的進步使得骨質疏鬆症的診斷更加準確和早期。人們對該疾病及其潛在後果的認知不斷提高，促使人們尋求醫療干涉和治療，從而增加了對骨質疏鬆症藥物的需求。

研究與開發投資不斷成長

骨質疏鬆症藥物研究的不斷擴大，加上主要生物製藥公司投資的增加、老年人口的不斷成長以及創新技術先進療法的出現，共同推動了全球骨質疏鬆症藥物市場的成長。

例如，2023 年 4 月，範安德爾研究所發表了一份報告，強調了導致骨密度降低的一個重要因素。這項發現有可能開發出更有效的藥物，對患有骨質疏鬆症的女性產生較少的副作用。由於骨質疏鬆症藥物研究的不斷增加、創新產品的監管批准不斷增加、老年人口不斷成長以及技術先進療法的進步，全球骨質疏鬆症藥物市場正在顯著擴張。

未來幾年，由於生技和製藥公司加大研發投資，市場可望成長。例如，2020年10月，義大利藥品監管機構批准了骨質疏鬆藥物雷洛昔芬的人體臨床研究。研究人員認為，這種治療也可能對 COVID-19 患者有潛在的好處，改善他們的健康並減少傳染。臨床試驗的積極結果可能會導致新治療方案的開發，從而推動未來的市場擴張。此外，全球骨質疏鬆症發生率在骨密度降低的人群中不斷增加，是促進市場成長的另一個重要因素。根據《加拿大骨質疏鬆症 2022》，超過 230 萬加拿大人患有骨質疏鬆症，其中 50 歲及以上成年人 80% 的骨折是由骨質疏鬆症造成的。

主要市場挑戰

嚴格的監管環境

嚴格的監管環境在減少骨質疏鬆症藥物的需求方面發揮了作用，主要是透過影響藥物的開發、行銷和取得。與所有藥物一樣，骨質疏鬆症藥物在獲得批准之前必須經過嚴格的臨床試驗並滿足嚴格的安全性和有效性標準。這些試驗可能非常耗時且耗費資源，從而延遲了新藥推向市場的時間。骨質疏鬆症患者可能無法及時獲得創新的治療方案，從而減少了對現有藥物的需求。

滿足監管要求通常會為製藥公司帶來大量的研發成本。這些成本可能會導致骨質疏鬆症藥物的價格上漲，這可能會限制患者的負擔能力並減少患者的使用機會。監管機構優先考慮病人安全是可以理解的。雖然這很重要，但嚴格的安全標準有時會阻礙某些藥物的供應。如果一種藥物顯示出即使很小的不良反應風險，從而導致對具有潛在益處的藥物的需求有限，情況尤其如此。

治療費用高昂

高昂的治療成本對骨質疏鬆症藥物市場供應商的成長構成了重大挑戰。骨質疏鬆症是一種以骨骼衰弱為特徵的疾病，需要長期治療以減輕疼痛並改善功能。然而，由於沒有任何治療方法可以逆轉關節損傷，患者常常面臨終生的治療疾病和使用藥物預防症狀的費用。此外，受各種健康狀況因素的影響，治療費用因地區而異。

根據美國疾病管制與預防中心 (CDC) 的數據，骨質疏鬆症是全球第二常見的健康狀況。這種廣泛的流行不僅給患者而且給醫療保健系統帶來了沉重的經濟負擔。預計與管理骨質疏鬆症相關的巨額成本將阻礙預測期內骨質疏鬆症藥物市場的成長。

解決高治療成本問題並探索創新解決方案至關重要，以使全世界患者更容易獲得和負擔得起骨質疏鬆症藥物。透過這樣做，我們可以減輕個人和醫療保健系統的經濟負擔，同時確保有效管理這種普遍的健康狀況。

主要市場趨勢

精準醫療

針對個人遺傳和生活方式因素量身定做的個人化骨質疏鬆症治療方法的開發即將到來。這種方法旨在最大限度地提高治療效果，同時最大限度地減少副作用。個人化醫療可以實現更精確的風險評估。有骨質疏鬆症家族史或特定遺傳傾向的患者可以及早發現，從而能夠採取主動干涉措施來預防骨質流失和骨折。個人化醫療可能涉及根據個人的遺傳和代謝特徵調整藥物劑量。這確保患者接受適量的藥物以獲得治療效果，同時最大限度地降低副作用的風險。

接受個人化治療的患者會接受持續監測和後續照護。這種積極主動的方法使醫療保健提供者能夠評估治療效果並根據需要進行調整，確保患者的骨骼健康保持最佳狀態。

新藥物標靶

正在進行的研究正在發現骨質疏鬆症藥物的新分子標靶。這些目標可能包括參與骨代謝的特定蛋白質或細胞途徑，為創新藥物開發提供機會。隨著對骨代謝分子機制的深入了解，研究人員可以設計專門針對這些機制的藥物。這包括開發小分子、抗體和其他與特定蛋白質或訊號路徑相互作用的治療劑。

正在進行的研究正在揭示有關骨質疏鬆症分子標靶的豐富知識。這些發現有可能徹底改變骨質疏鬆症藥物的開發，帶來更有效、更有針對性和個人化的治療，從而改善骨質疏鬆症患者的骨骼健康並降低骨折風險。

細分市場洞察

管理途徑見解

根據給藥途徑，骨質疏鬆症市場分為口服、注射和其他。口服藥物以其成本效益高且安全而聞名，儘管它們可能有輕微的副作用。據報道，有罕見的嚴重影響，例如頜骨壞死。然而，就有效性而言，口服藥物已被證明可以成功治療骨質疏鬆症。例如，阿崙膦酸鈉 (Fosamax) 已顯示其能夠將髖部骨折的風險降低 50%。值得注意的是，根據針對患者偏好的研究表明，患者通常更喜歡口服藥物，因為它們方便且可以避免注射或輸液。這種偏好凸顯了口服藥物在骨質疏鬆症治療的重要性。

地諾塞麥 (Prolia) 等注射藥物已成為治療骨質疏鬆症的高效選擇，具有即時的效果。這些藥物雖然通常是安全的，但確實可能會產生輕微的副作用。此外，使用它們還存在罕見但嚴重的下顎骨壞死 (ONJ) 風險。儘管有這些考慮，授予這些注射藥物的專利保護確保了排他性，讓製造商設定更高的價格。為了進一步擴大市場佔有率，製造商大量投資於行銷工作，進而影響處方模式。有趣的是，即使有替代治療選擇，患者的品牌忠誠度仍繼續推動骨質疏鬆症藥物市場。

藥物類型見解

從藥物類型來看，2022年雙磷酸鹽類藥物在骨質疏鬆症藥物市場中將佔據重要佔有率。這可以歸因於製藥業主要參與者加大了對先進新型雙磷酸鹽類藥物的研發投入。此外，雙磷酸鹽是治療骨質疏鬆症的廣泛處方藥物，這進一步推動了市場的成長。

另一方面，預計配體抑制劑領域在預測期內將出現最快的成長率。這主要是因為這些藥物專門用於治療骨轉移，透過充當表達其受體 RANK 的腫瘤細胞的骨化學引誘劑。因此，抑制 RANKL-RANK 路徑成為骨轉移的理想治療方法。對這些藥物類型的詳細了解和利用有助於骨質疏鬆症治療的進步，最終改善受該疾病影響的患者的生活品質。

區域洞察

從地區來看，北美在 2018 年佔據了主要佔有率，並且預計將繼續這一趨勢。這可以歸因於該地區容易獲得骨質疏鬆症藥物，從而促進了其成長。此外，骨質疏鬆症發病率的激增進一步刺激了對這些藥物的需求。

相反，預計亞太地區在預測期內將實現最快的成長。這可以歸因於該地區對使用骨質疏鬆症藥物的認知不斷提高。此外，不斷發展的生命科學產業一直是印度、中國和馬來西亞等發展中經濟體市場成長的關鍵驅動力。強勁市場的存在以及對研發活動的關注推動了這些地區骨質疏鬆症藥物市場的成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球骨質疏鬆藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型（副甲狀腺素治療、雙磷酸鹽、降鈣素、選擇性雌激素受體調節劑和其他藥物類型）
    • 依給藥途徑（口服、注射、其他）
    • 按應用（原發性骨質疏鬆症和繼發性骨質疏鬆症）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美骨質疏鬆藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 依給藥途徑
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲骨質疏鬆藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 藥品類型
    • 依給藥途徑
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區骨質疏鬆藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 藥品類型
    • 依給藥途徑
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲骨質疏鬆藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 藥品類型
    • 依給藥途徑
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲骨質疏鬆藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 藥品類型
    • 依給藥途徑
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非骨質疏鬆症藥物
    • 沙烏地阿拉伯骨質疏鬆症藥物
    • 阿拉伯聯合大公國骨質疏鬆藥物

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球骨質疏鬆藥物市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Eli Lilly and Company
    • Pfizer Inc.
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc.
    • Novartis International AG
    • Merck & Co. Inc.
    • Amgen Inc.
    • Radius Health Inc.
    • Actavis PLC

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 5081

The Global Osteoporosis Drugs Market, valued at USD 16.09 Billion in 2022, is poised for remarkable growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 5.73% through 2028.

Osteoporosis is a disease characterized by the deterioration of bone tissues and a decrease in bone strength. The diagnosis of this condition typically involves the use of various imaging techniques, including X-rays, computed tomography (CT), and magnetic resonance imaging (MRI).

Presently, a wide array of drugs is available in various formulations, ranging from standard tablets to intravenous (IV) infusions, to alleviate the symptoms of osteoporosis. These medications serve to restore the balance between bone resorption and formation, mend microscopic bone defects, reduce the risk of fractures, and enhance overall muscle strength in patients.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 16.09 Billion
Market Size 2028USD 22.36 Billion
CAGR 2023-20285.73%
Fastest Growing SegmentOnline Pharmacy
Largest MarketNorth America

Key Market Drivers

Increasing Incidences of Osteoporosis

The increasing incidences of osteoporosis are undeniably contributing to a significant rise in the demand for osteoporosis drugs. Osteoporosis, characterized by weakened bones that are more prone to fractures, primarily affects the elderly population, especially postmenopausal women. Osteoporosis disproportionately affects women, especially postmenopausal women, due to hormonal changes that accelerate bone loss. As the female population grows, so does the prevalence of osteoporosis, which directly fuels the demand for drugs designed to manage and mitigate the condition.

Growing Clinical Trials and Rising Geriatric Population

Osteoporosis is most common in the elderly, particularly postmenopausal women. With a globally aging population, there is a substantial increase in the number of individuals at risk of developing osteoporosis. As people age, their bone density naturally decreases, making osteoporosis more prevalent among seniors. - There is a significant and growing market opportunity in the field of research and development, as key players continue to invest in enhancing their technological capabilities. These investments are aimed at driving novel advancements that can meet the evolving needs of various industries. Additionally, the market is being influenced by the rising prevalence of osteoporosis, a condition characterized by weakened bones. This trend is creating a demand for innovative solutions that can effectively address the challenges posed by osteoporosis.

For instance, according to a report by the World Health Organization in 2022, the global population of individuals aged 60 and older is projected to reach one in six by the year 2030. By this point, the number of people over the age of 60 is expected to reach a staggering 1.4 billion, marking a significant increase from the 1 billion recorded in 2020. Looking further ahead, the number of individuals aged 60 or older is projected to double by 2050, reaching a staggering 2.1 billion. Furthermore, between 2020 and 2050, the number of people aged 80 or older is expected to triple, reaching a noteworthy 426 million.

These statistics paint a vivid picture of the demographic changes that are taking place globally, underscoring the need for innovative solutions that can cater to the needs of an aging population. As a result, the market for products and services aimed at addressing the challenges associated with aging, such as osteoporosis, is poised for significant growth and presents a unique opportunity for businesses operating in this space.

Improved Awareness and Diagnosis

Advances in medical knowledge and diagnostic technologies have led to more accurate and earlier diagnoses of osteoporosis. Increased awareness of the disease and its potential consequences prompts individuals to seek medical intervention and treatment, driving up the demand for osteoporosis drugs.

The Growing Investments in Research and Development

The expanding body of research on osteoporosis medications, coupled with increased investments by major biopharmaceutical companies, the growing elderly population, and the emergence of innovative technologically advanced therapies, collectively drive the growth of the global osteoporosis drug market.

For instance, in April 2023, the Van Andel Research Institute published a report highlighting a significant factor that contributes to reduced bone density. This discovery holds the potential for developing more efficient medications with fewer adverse effects for women with osteoporosis. The global osteoporosis drugs market is witnessing significant expansion due to increasing research studies on osteoporosis drugs, rising regulatory approvals for innovative products, a growing geriatric population, and advancements in technologically advanced therapies.

In the upcoming years, the market is poised to grow as a result of increased investment in research and development by biotechnology and pharmaceutical companies. For example, in October 2020, the Italian pharmaceutical regulatory body approved human clinical studies for the osteoporosis medicine raloxifene. Researchers believe that this treatment may also have potential benefits for individuals with COVID-19, improving their well-being and reducing contagion. Positive outcomes from clinical trials could lead to the development of new therapeutic options, thereby driving future market expansion. Furthermore, the increasing incidence of osteoporosis worldwide among individuals with reduced bone density is another important factor contributing to market growth. According to Osteoporosis Canada 2022, more than 2.3 million Canadians suffer from osteoporosis, with osteoporosis being responsible for 80% of fractures in adults aged 50 and older.

Key Market Challenges

Stringent Regulatory Environment

A stringent regulatory environment has played a role in decreasing the demand for osteoporosis drugs, primarily by impacting drug development, marketing, and access. Osteoporosis drugs, like all pharmaceuticals, must undergo rigorous clinical trials and meet stringent safety and efficacy criteria before gaining approval. These trials can be time-consuming and resource-intensive, delaying the introduction of new drugs to the market. Patients suffering from osteoporosis may not have timely access to innovative treatment options, decreasing demand for existing drugs.

Meeting regulatory requirements often entails substantial research and development costs for pharmaceutical companies. These costs can translate into higher prices for osteoporosis drugs, potentially limiting affordability and reducing patient access. Regulatory agencies, understandably, prioritize patient safety. While this is essential, the stringent safety standards can sometimes hinder the availability of certain drugs. This is particularly true if a drug shows even a remote risk of adverse effects, leading to limited demand for drugs with potential benefits.

High Costs Of Treatment

The high costs of treatment pose a significant challenge for the growth of the osteoporosis drugs market vendors. Osteoporosis, a condition characterized by weakened bones, requires long-term management to reduce pain and improve functions. However, as no therapy has the potential to reverse joint damage, patients often face life-long expenses for treating the disease and preventing symptoms using drugs. Moreover, the cost of treatments varies across regions, influenced by various health condition factors.

According to the Centers for Disease Control and Prevention (CDC), osteoporosis is the second most prevalent health condition treated globally. This widespread prevalence imposes a high financial burden not only on patients but also on healthcare systems. The substantial costs associated with managing osteoporosis are expected to hinder the growth of the osteoporosis drugs market during the forecast period.

It is crucial to address the issue of high treatment costs and explore innovative solutions to make osteoporosis drugs more accessible and affordable for patients worldwide. By doing so, we can alleviate the financial burden on individuals and healthcare systems while ensuring effective management of this prevalent health condition.

Key Market Trends

Precision Medicine

The development of personalized osteoporosis treatments tailored to an individual's genetic and lifestyle factors is on the horizon. This approach aims to maximize the effectiveness of therapies while minimizing side effects. Personalized medicine allows for more precise risk assessment. Patients with a family history of osteoporosis or specific genetic predispositions can be identified early, enabling proactive interventions to prevent bone loss and fractures. Personalized medicine may involve adjusting medication dosages based on an individual's genetic and metabolic characteristics. This ensures that patients receive the right amount of medication to achieve therapeutic benefits while minimizing the risk of side effects.

Patients undergoing personalized treatment receive ongoing monitoring and follow-up care. This proactive approach allows healthcare providers to assess treatment efficacy and make adjustments as needed, ensuring that the patient's bone health remains optimized.

Novel Drug Targets

Ongoing research is uncovering new molecular targets for osteoporosis drugs. These targets may include specific proteins or cellular pathways involved in bone metabolism, offering opportunities for innovative drug development. With a deeper understanding of the molecular mechanisms underlying bone metabolism, researchers can design drugs that specifically target these mechanisms. This includes the development of small molecules, antibodies, and other therapeutic agents tailored to interact with specific proteins or signaling pathways.

Ongoing research is uncovering a wealth of knowledge about the molecular targets involved in osteoporosis. These discoveries hold the potential to revolutionize the development of osteoporosis drugs, leading to more effective, targeted, and personalized treatments that improve bone health and reduce the risk of fractures in individuals living with this condition.

Segmental Insights

Route of Administration Insights

Based on the route of administration, the market for osteoporosis is segmented into oral, injectable, and others. Oral drugs are known for being cost-effective and safe, although they may have mild side effects. Rare serious effects, such as osteonecrosis of the jaw, have been reported. However, in terms of effectiveness, oral medications have proven successful in treating osteoporosis. For instance, alendronate (Fosamax) has shown its ability to reduce the risk of hip fractures by 50%. Notably, patients commonly prefer oral drugs due to their convenience and the avoidance of injections or infusions, as indicated by studies focusing on patient preferences. This preference highlights the importance of oral medications in the management of osteoporosis.

Injectable drugs like denosumab (Prolia) have emerged as highly effective options with immediate effects for treating osteoporosis. These medications, while generally safe, do come with the potential for mild side effects. Additionally, there is a rare but serious risk of osteonecrosis of the jaw (ONJ) associated with their use. Despite these considerations, the patent protection granted to these injectable drugs ensures exclusivity, allowing manufacturers to set higher prices. To further maximize their market presence, manufacturers heavily invest in marketing efforts, which in turn influence prescribing patterns. Interestingly, brand loyalty among patients continues to drive the Osteoporosis Drugs Market, even in the presence of alternative treatment options.

Drug Type Insights

In terms of Drug Type, the bisphosphonates accounted for a significant share of the osteoporosis drugs market in 2022. This can be attributed to the increased investment in research and development of advanced novel bisphosphonates drugs by major players in the pharmaceutical industry. Moreover, bisphosphonates are widely prescribed drugs for the treatment of osteoporosis, which further drives the growth of the market.

On the other hand, the rank ligand inhibitors segment is projected to witness the fastest growth rate during the forecast period. This is primarily due to the fact that these drugs are specifically used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells expressing its receptor, RANK. As a result, the inhibition of the RANKL-RANK pathway serves as an ideal treatment approach for bone metastasis. The detailed understanding and utilization of these drug types contribute to the advancement of osteoporosis treatment, ultimately improving the quality of life for patients affected by this condition.

Regional Insights

Region wise, North America accounted for the major share in 2018 and is expected to continue this trend. This can be attributed to the easy availability of osteoporosis drugs in the region, which has contributed to its growth. Additionally, the surge in the incidence of osteoporosis has further fueled the demand for these drugs.

On the contrary, Asia-Pacific is anticipated to register the fastest growth during the forecast period. This can be attributed to the increasing awareness regarding the use of osteoporosis drugs in the region. Furthermore, the constantly evolving life science industry has been a key driver of the market's growth in developing economies such as India, China, and Malaysia. The presence of a robust market and the focus on research and development activities have propelled the growth of the osteoporosis drugs market in these regions.

Key Market Players

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

Report Scope:

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Drug Type:

  • Parathyroid Hormone Therapy
  • Bisphosphonates
  • Calcitonin
  • Selective Estrogen Receptor Modulators
  • Other Drug Types

Osteoporosis Drugs Market, By Route of Administration:

  • Oral
  • Injectables
  • Others

Osteoporosis Drugs Market, By Application:

  • Primary Osteoporosis
  • Secondary Osteoporosis

Osteoporosis Drugs Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Osteoporosis Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations:

  • Global Osteoporosis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteoporosis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types)
    • 5.2.2. By Route of Administration (Oral, Injectables, Others)
    • 5.2.3. By Application (Primary Osteoporosis and Secondary Osteoporosis)
    • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route Of Administration
    • 6.2.3. By Application
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Osteoporosis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route Of Administration
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Osteoporosis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route Of Administration
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Osteoporosis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route Of Administration
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Distribution Channel

7. Europe Osteoporosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. Drug Type
    • 7.2.2. By Route Of Administration
    • 7.2.3. By Application
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Osteoporosis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route Of Administration
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. United Kingdom Osteoporosis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route Of Administration
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Italy Osteoporosis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route Of Administration
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. France Osteoporosis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route Of Administration
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Osteoporosis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route Of Administration
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Osteoporosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. Drug Type
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Application
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Osteoporosis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route Of Administration
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Osteoporosis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route Of Administration
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Osteoporosis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route Of Administration
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Osteoporosis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route Of Administration
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Osteoporosis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route Of Administration
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Distribution Channel

9. South America Osteoporosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. Drug Type
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Application
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Osteoporosis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route Of Administration
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Osteoporosis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route Of Administration
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Osteoporosis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route Of Administration
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Osteoporosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. Drug Type
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Application
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Osteoporosis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route Of Administration
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route Of Administration
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Osteoporosis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route Of Administration
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Osteoporosis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Eli Lilly and Company
    • 15.5.2. Pfizer Inc.
    • 15.5.3. F. Hoffmann-La Roche
    • 15.5.4. Teva Pharmaceutical Industries Ltd.
    • 15.5.5. GlaxoSmithKline plc.
    • 15.5.6. Novartis International AG
    • 15.5.7. Merck & Co. Inc.
    • 15.5.8. Amgen Inc.
    • 15.5.9. Radius Health Inc.
    • 15.5.10. Actavis PLC

16. Strategic Recommendations

17. About Us & Disclaimer